Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michael Kuzur
Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every 3 Weeks Increases and Maintains Hemoglobin Levels in Anemic Cancer Patients Undergoing Chemotherapy
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks Versus Epoetin Alfa Every Week for Cancer Patients Receiving Chemotherapy From a Us Payer's Perspective
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Strategies for the Use of Epoetin Alfa in Breast Cancer Patients
Oncologist
Cancer Research
Medicine
Oncology
Comparative Pharmacokinetics of Weekly and Every-Three-Weeks Docetaxel
Clinical Cancer Research
Cancer Research
Oncology
Once-Weekly Epoetin Beta Is Highly Effective in Treating Anaemic Patients With Lymphoproliferative Malignancy and Defective Endogenous Erythropoietin Production
British Journal of Haematology
Hematology
Weekly Versus Three Weeks Chemotherapy for Advanced Ovarian Cancer: A Meta-Analysis
Oncotarget
Oncology
Comparison of the Therapeutic Efficacy of Epoetin Beta and Epoetin Alfa in Maintenance Phase Hemodialysis Patients
Renal Failure
Medicine
Nephrology
Critical Care
Intensive Care Medicine
Epoetin Alfa in Platinum-Treated Ovarian Cancer Patients: Results of a Multinational, Multicentre, Randomised Trial
British Journal of Cancer
Cancer Research
Oncology
Epoetin Alpha Prevents Anaemia and Reduces Transfusion Requirements in Patients Undergoing Primarily Platinum-Based Chemotherapy for Small Cell Lung Cancer
British Journal of Cancer
Cancer Research
Oncology
Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa After Multiple Subcutaneous Administrations
Pharmacology
Medicine
Pharmacology
